Rosenberg, T., Rutherford, C., King, T., Tait, M.-A., Askeland, F. B.
& Nielsen, L. K. (2025).
Cross-Cultural Adaptation and Psychometric Validation of the Danish and Norwegian Versions of the Steroid Symptom Questionnaire for Multiple Myeloma (SSQ-MM). Abstract from Annual conference of International Society of Quality of Life Research, United States.
Nielsen, L. K., Rosenberg, T., Pedersen, A. K., Rutherford, C., King, T., Tait, M.-A., Haukås, E., Slørdahl, T. S.
, Klostergaard, A., Hermansen, E., Schjesvold, F. & Askeland, F. B. (2025).
Steroid-toxicity in newly diagnosed patients with multiple myeloma treated with a limited dexamethasone regimen; results from the NMSG REST study. Abstract from 67th American society of Hematology annual meeting and Exposition, Florida, United States.
Nielsen, L. K., Rosenberg, T., Pedersen, A. K., Rutherford, C., King, T., Tait, M.-A., Haukås, E., Slørdahl, T. S.
, Klostergaard, A., Hermansen, E., Schjesvold, F. & Askeland, F. B. (2025).
Steroid-toxicity in newly diagnosed patients with multiple myeloma treated with a limited dexamethasone regimen; results from the NMSG REST study. Abstract from Annual Conference of International Society of Quality of Life Research, United States.
Torpe, A. H., Thorsen, J., Iversen, K. F., Farmer, S., Lund, T., Hansen, C. T.
, Nielsen, L. K., Dahlager Jørgensen, N. G.
, Vase, M. Ø., Teodorescu, M., Salomo, M., Wennerström, C. & Szabo, A. G. (2025).
Real-world use, safety, and efficacy of teclistamab with or without prophylactic tocilizumab in relapsed/refractory multiple myeloma; Results from the danish ABCD study. Abstract from 67th American society of Hematology annual meeting and Exposition, Florida, United States.
Forde, K., Scouler, E., Cocks, K., Petranoviæ, D., Lehmann, J., Oerlemans, S., Stathopoulo, I. N., Constantinou, V.
, Nielsen, L. K., Alrjoub, W., Shamieh, O., Terpos, E. & Kyriakou, C. (2025).
Results from qualitative interviews with patients and healthcare professionals. Abstract from Annual Conference of International Society of Quality of Life Research, United States.
Torpe, A. H., Thorsen, J., Iversen, K. F., Farmer, S., Lund, T., Hansen, C. T.
, Nielsen, L. K., Dahlager Jørgensen, N. G.
, Vase, M. Ø., Teodorescu, M., Salomo, M., Wennerström, C. & Szabo, A. G. (2025).
Effectiveness, safety and clinical use of teclistamab in patients with triple-class-exposed multiple myeloma. Data from the Danish ABC-study. Abstract from 22nd Annual meeting, International Myeloma Society, Canada.
Forde, K., Scouler, E., Cocks, K., Petranoviæ, D., Lehmann, J., Oerlemans, S., Stathopoulo, I. N., Constantinou, V.
, Nielsen, L. K., Alrjoub, W., Shamieh, O., Terpos, E. & Kyriakou, C. (2025).
Update of the EORTC Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20). Results from the Phase I-II EORTC Prospective Study. Abstract from 22nd Annual meeting, International Myeloma Society, Canada.
Torpe, A. H., Thorsen, J., Iversen, K. F., Farmer, S., Lund, T., Hansen, C. T.
, Nielsen, L. K., Dahlager Jørgensen, N. G.
, Vase, M. Ø., Teodorescu, M., Wennerström, C., Salomo, M. & Szabo, A. G. (2025).
Real-world effectiveness of belantamab mafodotin, BCMA-CD3 bispecific antibodies and talquetamab in patients with triple-class-exposed multiple myeloma. First results from the Danish ABCD-study. Abstract from European Hematology Association 2025 Hybrid Congress, Italy, Italy.